The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting

BJU International

Volumn 108, Issue 11, 2011, Pages 1728-1733

  Adam, Ahmed ^a   Engelbrecht, Matthys J ^a   Bornman, Maria S ^a   Manda, Samuel O ^b   Moshokoa, Evelyn ^a   Feilat, Rasmi A ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

biomarker; Prostate CAncer gene 3; prostate histology; prostate specific antigen; South Africa

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTICAL EQUIPMENT; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; ETHNIC DIFFERENCE; GENETIC ANALYSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT PARAMETERS; PATIENT REFERRAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3 ASSAY; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TREATMENT INDICATION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TUMOR MARKERS, BIOLOGICAL;

EID: 80053105922     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10202.x     Document Type: Article

References (19)

1. Heyns CF, Naude AM, Visser AJ, et al,. Early diagnosis of prostate cancer in the Western Cape. S Afr Med J 2001; 91: 679-84 (Pubitemid 32816247)
2. Heyns CF,. Is prostate cancer more common and more aggressive in African men? Afr J Urol 2008; 14: 66-74
3. Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A,. The prostate cancer gene 3 assay: indications for use in clinical practice. BJU Int 2009; 105: 452-5
4. Mistry K, Cable G,. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16: 95-101
5. Morote Robles J, Ruibal Morell A, Palou Redorta J, de Torres Mateos JA, Soler Rosello A,. Clinical behaviour of prostate specific antigen and prostatic acid phosphatase: a comparative study. Eur Urol 1988; 14: 360-6
6. Salama G, Noirot O, Bataille V, et al,. Seasonality of serum prostate-specific antigen levels: a population-based study. Eur Urol 2007; 52: 708-14 (Pubitemid 47126126)
7. Bussemakers MJG, van Bokhoven A, Verhaegh GW, et al,. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9 (Pubitemid 30004960)
8. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P,. Urinary prostate cancer 3 test: toward the age of reason? J Urol 2010; 75: 447-53
9. Groskopf J, Aubin SM, Deras IL, et al,. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 2: 1089-95 (Pubitemid 43794421)
10. Park SB, Kim JK, Choi SH, Noh HN, Ji EK, Cho KS,. Prostate volume measurement by TRUS using heights obtained by transaxial and midsagittal scanning: comparison with specimen volume following radical prostatectomy. Korean J Radiol 2000; 1: 110-3
11. Eskew LA, Bare RL, McCullough DL,. Systematic 5 region biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-203 (Pubitemid 26414957)
12. Adam A, Adofo CK, Ijane KK, Dinkel JE, Feilat RA,. Spermatic cord liposarcoma and prostate adenocarcinoma: a synchronous association. Afr J Urol 2010; 16: 54-7
13. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei TJ,. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009; 115: 3879-86
14. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16 (Pubitemid 36741368)
15. Haese A, de la Taille A, van Poppel H, et al,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
16. Deras IL, Aubin SMJ, Blase A, et al,. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92
17. Fradet Y, Saad F, Aprikan A, et al,. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-5
18. Heyns CF, Naude AM, Ahmed G, Stopforth HB, Stellmacher GA, Visser AJ,. Serum prostate-specific antigen as a surrogate for the histological diagnosis of prostate cancer. S Afr Med J 2001; 91: 685-9
19. Rosario DJ, Lane JA, Metcalf C, et al,. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. Eur Urol 2008; 53: 777-84